PE20200677A1 - Composicion de cannabis - Google Patents
Composicion de cannabisInfo
- Publication number
- PE20200677A1 PE20200677A1 PE2019000307A PE2019000307A PE20200677A1 PE 20200677 A1 PE20200677 A1 PE 20200677A1 PE 2019000307 A PE2019000307 A PE 2019000307A PE 2019000307 A PE2019000307 A PE 2019000307A PE 20200677 A1 PE20200677 A1 PE 20200677A1
- Authority
- PE
- Peru
- Prior art keywords
- terpene fraction
- fraction
- cannabis extract
- terpene
- cbn
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Se refiere a una composicion farmaceutica que comprende un extracto de Cannabis y opcionalmente uno o mas portadores (aceite de sesamo), adyuvantes, diluyentes o excipientes farmaceuticamente aceptables, el extracto de Cannabis comprende una fraccion de cannabinoides y una fraccion de terpeno, en donde el extracto comprende ya sea : A: 0.3 % p/p de la fraccion de terpeno; 50 % p/p de Tetrahidrocannabinol (THC); 0.3 % p/p de Cannabigerol (CBG); y 0.5 % p/p de Cannabinodiol (CBN) o B: 0.5 % p/p de la fraccion de terpeno; 60 % p/p de CBD; 0.3 % p/p de THC; y 0.1 % p/p CBN; en donde la fraccion de terpeno comprende : beta-cariofileno al menos 11% en peso de la fraccion de terpeno, y uno o mas de linalool y beta-pineno. Tambien se refiere a un metodo para tratar el cancer de mama o un sintoma asociado con el cancer y al uso del extracto de Cannabis en la preparacion de un medicamento.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662370299P | 2016-08-03 | 2016-08-03 | |
| AU2017901222A AU2017901222A0 (en) | 2017-04-04 | Cannabis composition | |
| AU2017902065A AU2017902065A0 (en) | 2017-05-31 | Cannabis composition | |
| PCT/AU2017/050817 WO2018023166A1 (en) | 2016-08-03 | 2017-08-03 | Cannabis composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20200677A1 true PE20200677A1 (es) | 2020-06-11 |
Family
ID=65524553
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019000307A PE20200677A1 (es) | 2016-08-03 | 2017-08-03 | Composicion de cannabis |
| PE2021001332A PE20230607A1 (es) | 2016-08-03 | 2017-08-03 | Composicion de cannabis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001332A PE20230607A1 (es) | 2016-08-03 | 2017-08-03 | Composicion de cannabis |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11304925B1 (es) |
| EP (1) | EP3493800A4 (es) |
| JP (2) | JP2019526541A (es) |
| KR (3) | KR102447510B1 (es) |
| CN (1) | CN109789123A (es) |
| AU (4) | AU2017305103B2 (es) |
| BR (1) | BR112019001794A2 (es) |
| CA (1) | CA3031300A1 (es) |
| CL (1) | CL2019000266A1 (es) |
| CO (1) | CO2019001043A2 (es) |
| IL (1) | IL264458B (es) |
| MX (1) | MX2019001286A (es) |
| PE (2) | PE20200677A1 (es) |
| SG (1) | SG11201900501RA (es) |
| WO (1) | WO2018023166A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019001285A (es) | 2016-08-03 | 2019-06-13 | Zelda Therapeutics Operations Pty Ltd | Composicion de cannabis. |
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| WO2019002926A1 (en) * | 2017-06-27 | 2019-01-03 | Enviro BioMedical Laboratories Inc. | MIXTURE-TYPE CANNABIS COMPOUNDS AND PROCESSES FOR PREPARING THE SAME |
| CA3075122A1 (en) * | 2017-09-15 | 2019-03-21 | Zelda Therapeutics Operations Pty Ltd | Composition and method for treating autism |
| US11202771B2 (en) | 2018-01-31 | 2021-12-21 | Treehouse Biotech, Inc. | Hemp powder |
| US20230110830A1 (en) * | 2018-04-09 | 2023-04-13 | Ellevet Sciences | Hemp extract for treatment of pain in animals |
| WO2019227167A1 (en) * | 2018-06-01 | 2019-12-05 | The University Of Sydney | Compositions and treatments |
| US11946016B2 (en) | 2018-06-14 | 2024-04-02 | Biosoma B.V. | Process for the extraction of oil-soluble components from plant material |
| CA3119729A1 (en) | 2018-10-10 | 2020-04-16 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| WO2020084423A1 (en) * | 2018-10-24 | 2020-04-30 | Radient Technologies Innovations Inc. | Extraction-based contract execution |
| CA3123773A1 (en) * | 2018-12-12 | 2020-06-18 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Compositions and methods for the treatment of cutaneous t cell lymphoma (ctcl) |
| NL2022615B1 (en) * | 2019-02-21 | 2020-08-31 | Patrick Alexander Unger | Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight |
| US20240114949A1 (en) * | 2019-10-09 | 2024-04-11 | Nicoventures Trading Limited | Aerosolizable material |
| AU2021264109A1 (en) * | 2020-04-29 | 2022-12-08 | Ligar Limited Partnership | Imprinted polymers and methods for their use |
| CN115843248A (zh) * | 2020-06-12 | 2023-03-24 | 泽利拉治疗手术私人有限公司 | 用于治疗慢性疼痛的组合物和方法 |
| KR20220126653A (ko) * | 2021-03-08 | 2022-09-16 | 주식회사 엘지생활건강 | 칸나비게롤을 포함하는 조성물 |
| WO2022215071A1 (en) * | 2021-04-05 | 2022-10-13 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) | Compositions and methods for the treatment of cancer |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10051427C1 (de) * | 2000-10-17 | 2002-06-13 | Adam Mueller | Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte |
| GB2418612A (en) | 2004-10-01 | 2006-04-05 | Gw Pharma Ltd | Inhibition of tumour cell migration with cannabinoids |
| EP1827393A4 (en) | 2004-12-09 | 2012-04-18 | Insys Therapeutics Inc | DRONABINOL FORMULATIONS WITH LABORATORY TEMPERATURE |
| US20070060639A1 (en) | 2005-09-09 | 2007-03-15 | University Of Kentucky | Compositions and methods for intranasal delivery of tricyclic cannabinoids |
| US8980940B2 (en) | 2006-11-10 | 2015-03-17 | Johnson Matthey Public Limited Company | Stable cannabinoid compositions and methods for making and storing them |
| GB2478595B (en) | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
| GB201117956D0 (en) | 2011-10-18 | 2011-11-30 | Otsuka Pharma Co Ltd | Phytocannabinoids for use in the treatment of breast cancer |
| SI2844243T1 (sl) * | 2012-05-03 | 2020-02-28 | Echo Pharmaceuticals B.V. | Metoda za pripravo izolata iz rastline konoplje, ki obsega delta-9-tetrahidrokanabinol |
| EP2968259B1 (en) * | 2013-03-14 | 2022-09-14 | SC Laboratories Inc. | Bioactive concentrates and uses thereof |
| MX2015013202A (es) * | 2013-03-15 | 2016-04-07 | Biotech Inst Llc | Cultivo, produccion, procesamiento y uso de cannabis de especialidad. |
| SI3062606T1 (sl) | 2013-10-29 | 2019-09-30 | Biotech Institute, Llc | Gojenje, priprava, predelava in uporaba posebnega kanabisa |
| US9044390B1 (en) | 2014-04-17 | 2015-06-02 | Gary J. Speier | Pharmaceutical composition and method of manufacturing |
| WO2015200049A1 (en) * | 2014-06-26 | 2015-12-30 | Island Breeze Systems Ca, Llc | Mdi related products and methods of use |
| EP3217995A1 (en) * | 2014-08-25 | 2017-09-20 | Janing Holding ApS | Device with compositions for delivery to the lungs, the oral mucosa and the brain |
| EP3209312A1 (en) | 2014-10-21 | 2017-08-30 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
| CN107205981A (zh) | 2014-12-12 | 2017-09-26 | 奥海能量公益公司 | 微胶囊化大麻素组合物 |
| US10502750B2 (en) * | 2014-12-23 | 2019-12-10 | Biotech Institute, Llc | Reliable and robust method for the analysis of cannabinoids and terpenes in cannabis |
| EP3250200A4 (en) | 2015-01-31 | 2018-09-19 | Constance Therapeutics, Inc. | Methods for preparation of cannabis oil extracts and compositions |
| AU2017307644B2 (en) | 2016-08-03 | 2019-06-20 | Zelira Therapeutics Operations Pty Ltd | Cannabis composition |
| MX2019001285A (es) | 2016-08-03 | 2019-06-13 | Zelda Therapeutics Operations Pty Ltd | Composicion de cannabis. |
-
2017
- 2017-08-03 JP JP2019505187A patent/JP2019526541A/ja active Pending
- 2017-08-03 SG SG11201900501RA patent/SG11201900501RA/en unknown
- 2017-08-03 PE PE2019000307A patent/PE20200677A1/es unknown
- 2017-08-03 KR KR1020217033707A patent/KR102447510B1/ko active IP Right Grant
- 2017-08-03 BR BR112019001794-1A patent/BR112019001794A2/pt active Search and Examination
- 2017-08-03 KR KR1020197005323A patent/KR20190034576A/ko active Application Filing
- 2017-08-03 CN CN201780060641.8A patent/CN109789123A/zh active Pending
- 2017-08-03 PE PE2021001332A patent/PE20230607A1/es unknown
- 2017-08-03 CA CA3031300A patent/CA3031300A1/en active Pending
- 2017-08-03 WO PCT/AU2017/050817 patent/WO2018023166A1/en active Search and Examination
- 2017-08-03 EP EP17836100.2A patent/EP3493800A4/en active Pending
- 2017-08-03 MX MX2019001286A patent/MX2019001286A/es unknown
- 2017-08-03 US US15/780,579 patent/US11304925B1/en active Active
- 2017-08-03 KR KR1020227032758A patent/KR20220132674A/ko not_active Application Discontinuation
- 2017-08-03 AU AU2017305103A patent/AU2017305103B2/en active Active
-
2018
- 2018-07-03 AU AU2018100920A patent/AU2018100920B4/en active Active
-
2019
- 2019-01-24 IL IL264458A patent/IL264458B/en active IP Right Grant
- 2019-01-31 CL CL2019000266A patent/CL2019000266A1/es unknown
- 2019-02-01 CO CONC2019/0001043A patent/CO2019001043A2/es unknown
- 2019-05-20 AU AU2019203529A patent/AU2019203529B2/en active Active
-
2020
- 2020-12-09 JP JP2020204014A patent/JP7139559B2/ja active Active
-
2021
- 2021-07-16 AU AU2021205115A patent/AU2021205115B2/en active Active
-
2022
- 2022-03-16 US US17/696,684 patent/US20220202767A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL264458A (en) | 2019-02-28 |
| BR112019001794A2 (pt) | 2019-05-07 |
| EP3493800A1 (en) | 2019-06-12 |
| AU2018100920A4 (en) | 2018-08-02 |
| AU2019203529B2 (en) | 2021-04-29 |
| EP3493800A4 (en) | 2020-04-08 |
| KR20220132674A (ko) | 2022-09-30 |
| AU2018100920B4 (en) | 2019-02-07 |
| AU2021205115B2 (en) | 2023-06-15 |
| PE20230607A1 (es) | 2023-04-13 |
| KR20210129747A (ko) | 2021-10-28 |
| AU2019203529A1 (en) | 2019-06-06 |
| CL2019000266A1 (es) | 2019-10-04 |
| US11304925B1 (en) | 2022-04-19 |
| AU2017305103B2 (en) | 2019-02-21 |
| US20220202767A1 (en) | 2022-06-30 |
| AU2021205115A1 (en) | 2021-08-12 |
| AU2017305103A1 (en) | 2018-07-05 |
| CN109789123A (zh) | 2019-05-21 |
| IL264458B (en) | 2021-06-30 |
| JP7139559B2 (ja) | 2022-09-21 |
| KR102447510B1 (ko) | 2022-09-27 |
| WO2018023166A1 (en) | 2018-02-08 |
| JP2021054836A (ja) | 2021-04-08 |
| SG11201900501RA (en) | 2019-02-27 |
| CA3031300A1 (en) | 2018-02-08 |
| CO2019001043A2 (es) | 2020-06-19 |
| NZ750272A (en) | 2021-09-24 |
| JP2019526541A (ja) | 2019-09-19 |
| KR20190034576A (ko) | 2019-04-02 |
| MX2019001286A (es) | 2019-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200677A1 (es) | Composicion de cannabis | |
| CO2019013887A2 (es) | Composiciones y tratamientos para el trastorno del sueño | |
| PE20200726A1 (es) | Composicion de cannabis | |
| CL2019000268A1 (es) | Composición de cannabis. | |
| CL2017002996A1 (es) | Compuestos alqueno tetrasustituidos y su uso | |
| MX2020003934A (es) | Uso de cannabidiol en combinacion con agonistas del receptor 5-ht2b o anfetamina en el tratamiento de la epilepsia. | |
| CO2017004974A2 (es) | Extractos de cannabis y métodos de preparación. | |
| CL2020003368A1 (es) | Composicion y metodo para tratar el dolor | |
| FI3743053T3 (fi) | Kannabinoidien käyttö epilepsian hoidossa | |
| SV2017005489A (es) | Terapias de combinación para el tratamiento de cánceres | |
| CL2020000632A1 (es) | Composición y método para el tratamiento del autismo. | |
| ECSP21075073A (es) | Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicoactivos | |
| CL2016000008A1 (es) | Tratamiento de lesiones inflamatorias de rosacea con ivermectina. | |
| AR112102A1 (es) | Tinostamustina para utilizar en el tratamiento de cáncer de ovario | |
| PE20200338A1 (es) | Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil | |
| CO2021001057A2 (es) | Composición y método para el ahorro de opioides | |
| MX2020004232A (es) | Composiciones de cannabinoides y sus metodos de uso. | |
| CR20150653A (es) | Compuestos nuevos para el tratamiento del cáncer | |
| CO2021001059A2 (es) | Composición de cannabinoides y método para tratar el ptsd y/o la ansiedad | |
| MX364633B (es) | Uso de cannabinoides en el tratamiento de enfermedades degenerativas del músculo esquelético. | |
| CL2015002466A1 (es) | Formulaciones de compuestos orgánicos | |
| CO2019000604A2 (es) | Composición vaginal que comprende una combinación de estrógeno y vitamina d | |
| NI202000017A (es) | Composición farmacéutica para la prevención o el tratamiento de enfermedades cardiovasculares acompañadas por diabetes, que incluye amlodipino, losartán y rosuvastatina, y preparación compuesta que incluye los mismos | |
| CO2021006279A2 (es) | Métodos y tratamientos para la disfunción eréctil | |
| NZ727509A (en) | Use of cannabinoids in the treatment of epilepsy |